No vaccine is yet available for respiratory syncytial virus (RSV), which causes lung infections that, while usually mild, can be deadly for very young children. Biotech startup Meissa Vaccines, which aims to fill that treatment gap, announced today it raised $30 million to fund early-stage clinical trials for its experimental RSV vaccine.

Morningside Ventures, a private equity and venture capital firm founded in Hong Kong in 1986, was the sole investor in the Series A financing, which brings Meissa’s fundraising total to nearly $34 million. The startup is a resident company at Johnson & Johnson Innovation’s facility JLABS in South San… Read more »

UNDERWRITERS AND PARTNERS